Interfering with mitochondrial dynamics sensitizes glioblastoma multiforme to temozolomide chemotherapy
Open Access
- 28 December 2021
- journal article
- research article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 26 (3) , 893-912
Abstract
Glioblastoma multiforme (GBM) is a primary tumour of the central nervous system (CNS) that exhibits the highest degree of malignancy. Radiotherapy and chemotherapy are essential to prolong the survival time of patients. However, clinical work has demonstrated that sensitivity of GBM to chemotherapy decreases with time. The phenomenon of multi‐drug resistance (MDR) reminds us that there may exist some fundamental mechanisms in the process of chemo‐resistance. We tried to explore the mechanism of GBM chemo‐resistance from the perspective of energy metabolism. First, we found that the oxidative phosphorylation (OXPHOS) level of SHG44 and U87 cells increased under TMZ treatment. In further studies, it was found that the expression of PINK1 and mitophagy flux downstream was downregulated in GBM cells, which were secondary to the upregulation of TP53 in tumour cells under TMZ treatment. At the same time, we examined the mitochondrial morphology in tumour cells and found that the size of mitochondria in tumour cells increased under the treatment of TMZ, which originated from the regulation of AMPK on the subcellular localization of Drp1 under the condition of unbalanced energy supply and demand in tumour cells. The accumulation of mitochondrial mass and the optimization of mitochondrial quality accounted for the increased oxidative phosphorylation, and interruption of the mitochondrial fusion process downregulated the efficiency of oxidative phosphorylation and sensitized GBM cells to TMZ, which was also confirmed in the in vivo experiment. What is more, interfering with this process is an innovative strategy to overcome the chemo‐resistance of GBM cells.Keywords
Funding Information
- People's Government of Jilin Province (2019C031)
This publication has 52 references indexed in Scilit:
- Mutant p53: one name, many proteinsGenes & Development, 2012
- Acquisition of Temozolomide Chemoresistance in Gliomas Leads to Remodeling of Mitochondrial Electron Transport ChainJournal of Biological Chemistry, 2010
- Membrane Remodeling Induced by the Dynamin-Related Protein Drp1 Stimulates Bax OligomerizationCell, 2010
- Inhibition of Drp1-dependent mitochondrial fragmentation and apoptosis by a polypeptide antagonist of calcineurinCell Death & Differentiation, 2010
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Mitochondrial fission factor Drp1 is essential for embryonic development and synapse formation in miceNature Cell Biology, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- The γ‐H2A.X: Is it just a surrogate marker of double‐strand breaks or much more?Environmental and Molecular Mutagenesis, 2007
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Quantification of ATP‐producing and consuming processes of Ehrlich ascites tumour cellsEuropean Journal of Biochemistry, 1986